ImmunoGen Named One of The Boston Globe's Top Places to Work for Third Consecutive Year
November 13 2015 - 8:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops targeted anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that it has been named
one of The Boston Globe's Top Places to Work. The Company has
received this recognition for the third consecutive year and in
four of the last five years.
“We are extremely pleased that ImmunoGen has once again been
recognized as one of The Boston Globe's Top Places to Work,”
commented Daniel Junius, President and CEO. “It is the expertise
and dedication of our entire organization that has brought
ImmunoGen to where we are today: a company with a validated
technology, a highly promising lead product program moving into a
study we intend to use for registration purposes, a rich pipeline
and partnerships with a number of leading healthcare companies. We
are proud that we continue to attract and retain employees who are
committed to our mission of making a difference in the lives of
patients with cancer.”
The Boston Globe's 2015 Top Places to Work recognizes the most
admired workplaces in the state. The rankings in Top Places to Work
are based on confidential survey information collected by
WorkplaceDynamics, an independent company specializing in employee
engagement and retention, from nearly 77,000 individuals at a wide
array of Massachusetts organizations. The survey measures employee
opinions about their company’s direction, execution, connection,
management, work, pay and benefits, and engagement. The winners
share a few key traits, including offering progressive benefits,
giving their employees a voice, and encouraging them to have some
fun while they’re at it.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted anticancer therapeutics using its proprietary ADC
technology. The Company's lead product candidate, mirvetuximab
soravtansine, is a potential treatment for FRα-positive ovarian
cancer and other solid tumors. A number of major healthcare
companies have licensed limited rights to use ImmunoGen's ADC
technology to develop anticancer therapies; it is used in Roche's
marketed product, Kadcyla®. More information about the Company can
be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including mirvetuximab soravtansine
(IMGN853), including risks related to clinical studies and
regulatory processes, their timings and results. A review of these
risks can be found in ImmunoGen's Annual Report on Form 10-K for
the fiscal year ended June 30, 2015 and other reports filed with
the Securities and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151113005123/en/
ImmunoGen, Inc.Carol Hausner, 781-895-0600info@immunogen.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024